Désirée van der Heijde

Désirée van der Heijde publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Désirée van der Heijde sits on this spectrum.

Désirée van der Heijde D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Désirée van der Heijde sits on this spectrum.

Research.com Recognitions

• 2025 - Research.com Best Female Scientists Award
• 2025 - Research.com Best Scientists Award
• 2023 - Research.com Medicine in Netherlands Leader Award

Overview

Best Publications

• EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update

  Josef S Smolen;Robert Landewé;Ferdinand C Breedveld;Maya Buch;Maya Buch

  5227
  Citations

• Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group.

  P E Lipsky;D M van der Heijde;E W St Clair;D E Furst

  4728
  Citations

• The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection

  M Rudwaleit;D van der Heijde;R Landewé;J Listing

  4261
  Citations

• Treating rheumatoid arthritis to target: recommendations of an international task force

  Josef S. Smolen;Daniel Aletaha;Johannes W J W Bijlsma;Ferdinand C Breedveld

  2914
  Citations

• Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial

  Lars Klareskog;Désirée van der Heijde;Julien P de Jager;Andrew Gough

  2688
  Citations

• The Assessment of SpondyloArthritis international Society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general

  M. Rudwaleit;D.M.F.M. van der Heijde;R.B.M. Landewé;N. Akkoc

  1883
  Citations

• American College of Rheumatology/European League Against Rheumatism Provisional Definition of Remission in Rheumatoid Arthritis for Clinical Trials

  David T. Felson;David T. Felson;Josef S. Smolen;George Wells;Bi Zhang

  1833
  Citations

• 2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis

  Désirée van der Heijde;Sofia Ramiro;Robert Landewé;Xenofon Baraliakos

  1715
  Citations

• Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force

  Josef S Smolen;Ferdinand C Breedveld;Gerd R Burmester;Vivian Bykerk

  1680
  Citations

• Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis

  Maarten Boers;Arco C Verhoeven;Harry M Markusse;Mart Afj van de Laar

  1585
  Citations

• Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial

  E William St Clair;Désirée M F M van der Heijde;Josef S Smolen;Ravinder N Maini

  1562
  Citations

• The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part I): classification of paper patients by expert opinion including uncertainty appraisal

  M Rudwaleit;R Landewé;D van der Heijde;J Listing

  1156
  Citations

• Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial.

  Désirée van der Heijde;Alan Kivitz;Michael H. Schiff;Joachim Sieper

  1155
  Citations

• Age at disease onset and diagnosis delay in HLA-B27 negative vs. positive patients with ankylosing spondylitis

  Ernst Feldtkeller;Muhammad Asim Khan;Désirée van der Heijde;Sjef van der Linden

  1121
  Citations

• European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update.

  L Gossec;J S Smolen;S Ramiro;M de Wit

  1096
  Citations

• Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT).

  Désirée van der Heijde;Ben Dijkmans;Piet Geusens;Joachim Sieper

  1077
  Citations

• Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab

  Norihiro Nishimoto;Jun Hashimoto;Nobuyuki Miyasaka;Kazuhiko Yamamoto

  1047
  Citations

• Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2) : a randomised, double-blind, placebo-controlled, phase 3 trial

  Iain B McInnes;Philip J Mease;Bruce Kirkham;Arthur Kavanaugh

  1004
  Citations

• Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial.

  John C. Davis;Désirée Van Der Heijde;Jurgen Braun;Maxime Dougados

  963
  Citations

• Nonsteroidal antiinflammatory drugs reduce radiographic progression in patients with ankylosing spondylitis: A randomized clinical trial

  Astrid Wanders;Désirée van der Heijde;Robert Landewé;Jéhan-Michel Béhier

  937
  Citations